Small molecule oral targeted therapies in ulcerative colitis

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Ulcerative colitis (UC) incidence and prevalence are rising globally.
• The exact cause and pathogenesis of UC remain unclear, but research has improved understanding and identified new therapeutic targets.
• Biologic therapies have significantly altered inflammatory bowel disease management.

Purpose of the Study:

• To provide a comprehensive overview of oral therapies for ulcerative colitis (UC).
• To review approved, developing, and preclinical oral small molecule treatments for UC.
• To inform clinicians about current and future oral treatment options for UC.

Main Methods:

• Review of approved oral therapies for ulcerative colitis.
• Analysis of oral small molecule drugs currently in development for UC.
• Examination of preclinical studies for potential future UC therapies.

Main Results:

• Small molecule oral therapies are emerging as a significant advancement in UC treatment.
• Oral administration offers advantages over infusion therapies, including ease of use, patient acceptance, and cost reduction.
• The review details both currently available and anticipated oral treatments for UC.

Conclusions:

• Oral small molecule therapies represent a substantial shift in ulcerative colitis management.
• These therapies offer significant advantages, improving patient experience and potentially reducing healthcare costs.
• The ongoing development of oral treatments promises further advancements in managing this chronic condition.